Is Privia Health Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Privia Health Group, Inc. moved from expensive to very expensive. This indicates that the company is overvalued, particularly when considering its high P/E ratio of 181, a price-to-book value of 4.29, and an EV to EBITDA of 82.17. In comparison to peers, Globe Life, Inc. has a fair P/E of 11.82, while Lincoln National Corp. boasts a very attractive P/E of 6.96, highlighting the significant premium at which Privia is trading.
Despite its recent stock performance, where it outperformed the S&P 500 with a year-to-date return of 30.59% compared to the index's 13.30%, the valuation metrics suggest that the stock is not justified at its current price levels. The combination of high valuation ratios and the peer comparison strongly supports the conclusion that Privia Health Group, Inc. is overvalued.